Immunosuppressive therapy to mitigate Anti-soluble alkaline phosphatase immune response
EP4757810A1Pending Publication Date: 2026-06-17ALEXION PHARMACEUTICALS INC
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- ALEXION PHARMACEUTICALS INC
- Filing Date
- 2024-08-02
- Publication Date
- 2026-06-17
AI Technical Summary
Technical Problem
Patients with hypophosphatasia (HPP) undergoing enzyme replacement therapy (ERT) with soluble alkaline phosphatase (sALP) may develop neutralizing antibodies, leading to reduced efficacy of the treatment.
Method used
Administering a therapy that includes a dihydrofolate reductase (DHFR) inhibitor, such as methotrexate, and an anti-CD20 antibody, such as rituximab, in combination with a proteasome inhibitor like bortezomib, to reduce the amount, formation, or effect of anti-sALP immune responses.
Benefits of technology
The proposed therapy effectively decreases the risk or reduces the effect of antibodies specific for sALP, thereby maintaining or restoring the efficacy of sALP ERT in patients with HPP.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024040680_13022025_PF_FP_ABST
Abstract
The disclosure features methods for treating neutralizing antibodies that reduce the efficacy of soluble alkaline phosphatase treatment (e.g., asfotase alfa), an enzyme replacement therapy, such as for the treatment of bone mineralization disorders, e.g., hypophosphatasia (HPP). The methods include diagnosing a subject as having the presence of neutralizing antibodies that affect the efficacy of treatment, administering a treatment suitable for reducing the deleterious effects of neutralizing antibodies, and continuing alkaline phosphatase treatment.
Need to check novelty before this filing date? Find Prior Art